Opioid Drug Interaction Study

Phase 1/2 Recruiting 25 enrolled Shanna Babalonis, PhD National Institute on Drug Abuse (NIDA) · collab

RandomizedFactorialDouble-blindBasic science

Summary

This study will examine the effects of doses of opioid/placebo and doses of alprazolam/placebo, alone and in combination. The primary outcomes are pharmacodynamic measures (subjective ratings of drug liking and other abuse-related effects; physiological outcomes) and pharmacokinetic outcomes (from blood samples) to determine the interaction effects of these compounds.

Timeline

Start: 2025-04-01
Primary completion: 2029-01-01
Completion: 2029-06-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Alprazolam	Small molecule	—	Oral
Subject	Oxycodone	Other / unclassified	—	Oral

Indications

No indication recorded.